2-Acetamino-6-methyl-pyrazin | 5594-16-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Acetamino-6-methyl-pyrazin
• 英文别名: N-(6-methyl-pyrazin-2-yl)-acetamide；N-(6-Methyl-pyrazin-2-yl)-acetamid；N-(6-methylpyrazin-2-yl)acetamide
• CAS: 5594-16-1
• 化学式: C₇H₉N₃O
• 分子量: 151.168
• InChiKey: CQSBMYKHFNBFOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Acetamino-6-methyl-pyrazin 在 potassium permanganate 、 溴 作用下， 生成 6-acetylamino-5-bromo-pyrazine-2-carboxylic acid
  参考文献：
  名称：

  Synthesis of 2,6-Disubstituted Pyrazines and Related Derivatives

  摘要：

  DOI：

  10.1021/jo01085a016

文献信息

• BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
  申请人：Genfleet Therapeutics (Shanghai) Inc.

  公开号：EP3967682A1

  公开（公告）日：2022-03-16

  Provided are a substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition, also disclosed are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.

  提供的是如公式I所示的一种替代二氢吡唑酮化合物，该化合物对RIPK1具有选择性抑制作用，以及其药用盐、立体异构体、溶剂合物或前药，其中公式中每个基团的定义在描述中有详细说明。此外，还披露了含有该化合物的药物组合物，以及在制备治疗RIPK1相关疾病或症状的药物中的使用。
• SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20140088076A1

  公开（公告）日：2014-03-27

  The invention provides novel compounds having the general formula: wherein X 1 is N or N + O − , and one of X 2 , X 3 and X 4 is N or N + —O − and the remainder of X 2 , X 3 and X 4 is C. R 2 , R 3 , R 4 , R 5 , R 6 . A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.

  该发明提供了具有一般式的新化合物：其中X1是N或N+O−，而X2、X3和X4中的一个是N或N+—O−，而X2、X3和X4的其余部分是C。R2、R3、R4、R5、R6、A、B和Y如本文所述。此外，本文还进一步描述了公式I的组合物化合物和使用方法。
• RING-FUSED HETEROCYCLIC COMPOUND
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20150284384A1

  公开（公告）日：2015-10-08

  The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. [wherein, R 1 represents optionally substituted lower alkyl and the like, R 2 represents optionally substituted lower alkyl and the like, R 3 represents the formula (II): (wherein, n represents 0 or 1, R 3a represents a hydrogen atom and the like, R 3b represents a hydrogen atom and the like, and R 3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W 1 represents a nitrogen atom and the like, W 2 represents a nitrogen atom and the like]

  根据本发明，环融合杂环化合物或其药学上可接受的盐具有T型钙通道调节作用，例如，可用作治疗和/或预防瘙痒的药物。本发明提供了由以下一般式(I)或其药学上可接受的盐等表示的环融合杂环化合物，具有T型钙通道调节作用，可用作治疗和/或预防瘙痒等疾病的治疗和/或预防剂。其中，R1代表可选取代的低碳基等，R2代表可选取代的低碳基等，R3代表公式(II)：（其中，n代表0或1，R3a代表氢原子等，R3b代表氢原子等，R3c代表氢原子等）等，Q代表氢原子等，W1代表氮原子等，W2代表氮原子等。
• [EN] QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE QUINUCLIDINE UTILISÉS COMME ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES M3
  申请人：ASTRAZENECA AB

  公开号：WO2009138707A9

  公开（公告）日：2010-01-28
• CONDENSED RING HETEROCYCLIC COMPOUND
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2881394B1

  公开（公告）日：2018-03-21